dromlakhani Treat with bisphosphonate in Paget's disease with congestive heart failure
STEP 1 — Gather Information
Confirm Paget's disease diagnosis via clinical features, plain radiographs, radionuclide bone scan, and elevated bone turnover markers (total ALP or P1NP/BSAP/CTx). Assess for congestive heart failure: symptoms (dyspnea, orthopnea, PND), signs (elevated JVP, peripheral edema, S3 gallop), BNP/NT-proBNP, echocardiogram for high-output state, and basic labs (renal function, calcium, vitamin D). Review contraindications to bisphosphonate (eGFR <35 mL/min, untreated hypocalcemia, pregnancy).
STEP 2 — Rule In / Rule Out
Rule in if both active Paget's disease (elevated bone turnover marker or radiographic/scan evidence) and symptomatic congestive heart failure are present. Rule out if either condition is absent or if a contraindication to bisphosphonate exists (severe renal impairment, uncorrected hypocalcemia).
STEP 3 — Classify or Stratify
Stratify by CHF severity (NYHA class I‑IV) and Paget's disease extent (monostotic vs polyostotic). For NYHA class II‑IV or polyostotic disease, prefer potent IV bisphosphonate; for NYHA I with monostotic disease and no contraindication, oral bisphosphonate may be considered.
STEP 4 — Decide
If no contraindication, administer a single 5 mg IV zoledronate infusion over 15 minutes (pre‑hydrate, ensure vitamin D sufficiency, correct calcium). If zoledronate contraindicated, use an oral bisphosphonate (e.g., alendronate 40 mg daily for 6 months). Reassess bone turnover markers and cardiac symptoms at 3‑6 months.
Clinical Guardrails / Mimics / Pitfalls
Do not give bisphosphonate in severe renal impairment (eGFR <35) without dose adjustment; avoid in untreated vitamin D deficiency or hypocalcemia due to risk of symptomatic hypocalcemia post‑infusion. Do not rely solely on symptoms to assess CHF response; use objective markers (BNP, echocardiogram). Avoid in pregnancy or breastfeeding. Monitor for acute phase reaction (fever, myalgias) and treat with acetaminophen/NSAIDs prophylactically.
Concrete Clinical Example
A 70‑year‑old woman with known polyostotic Paget's disease (ALP 280 U/L, bone scan showing widespread uptake) presents with progressive dyspnea on exertion, orthopnea, BNP 620 pg/mL, and echocardiogram showing high‑output heart failure. Her eGFR is 55 mL/min, vitamin D 32 ng/mL, calcium normal. After confirming no contraindication, she receives zoledronate 5 mg IV. At 4 months, ALP falls to 110 U/L, BNP decreases to 210 pg/mL, and dyspnea improves.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2910